pyrazines has been researched along with Lymphoma in 43 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.33) | 18.7374 |
| 1990's | 2 (4.65) | 18.2507 |
| 2000's | 21 (48.84) | 29.6817 |
| 2010's | 18 (41.86) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S; Liu, S; Wen, F; Xu, H; Yi, M; Yuan, X | 1 |
| Cheung, YK | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Bhagat, G; Furman, RR; Gardner, JR; Gonen, M; Gueorguiev, VD; Heaney, ML; Manova, K; O'Connor, OA; Paoluzzi, L; Scotto, L | 1 |
| Au, WY; Kwong, YL; Liang, RH; Shen, L; Shimizu, N; Srivastava, G; Tsuchiyama, J; Wong, KY | 1 |
| Balasubramanian, S; Bhalla, S; Buggy, J; David, K; Evens, AM; Gordon, LI; Mauro, L; Miller, R; Prachand, S; Sirisawad, M | 1 |
| Gerecitano, J | 1 |
| Chen, ST; Gaffney, KJ; Louie, SG; Petasis, NA; Schönthal, AH; Thomas, S | 1 |
| Bannerman, B; Berger, A; Blank, J; Bolen, J; Bruzzese, F; Cao, Y; Dick, L; Fitzgerald, M; Fleming, P; Garcia, K; Hales, P; Kupperman, E; Lee, EC; Liu, J; Manfredi, M; Rolfe, M; Tsu, C; Yang, Y; Yu, J; Yu, L | 1 |
| Cai, Z; Chung, V; Guan, M; Huang, H; Yen, Y; Zheng, W; Zhu, L | 1 |
| Huang, HB; Wu, SQ; Zhan, R | 1 |
| Aicher, B; Blau, IW; Busse, A; Dabrowski, R; Lohneis, P; Schmidt-Hieber, M; Thiel, E; Weimann, A | 1 |
| Cavalli, F; Johnston, PB; Witzig, TE; Yuan, R | 1 |
| Fujiwara, S; Gotoh, K; Isobe, Y; Ito, Y; Iwata, S; Kawada, J; Kimura, H; Nishiyama, Y; Sugimoto, K; Ushijima, Y; Yano, S | 1 |
| Aujay, M; Azab, AK; Azab, F; Ghobrial, IM; Issa, GC; Liu, Y; Maiso, P; Morgan, B; Ngo, HT; Quang, P; Roccaro, AM; Sacco, A; Zhang, Y | 1 |
| Dreyling, M | 1 |
| Reid, EG | 1 |
| Ambinder, RF; Baechler, S; Esaias, C; Fu, DX; Hobbs, RF; Pomper, MG; Sgouros, G | 1 |
| Chang, HC; De La Rosa, M; Han, L; Lupov, IP; Oza, K; Pelloso, D; Robertson, MJ; Sahu, RP; Schwartz, A; Travers, JB; Voiles, L | 1 |
| Gopinathan, G; Gribben, JG; Jia, L; Sukumar, JT | 1 |
| Kim, WS; Lee, SJ; Park, C; Yeom, SY | 1 |
| Iida, S | 1 |
| Ogura, M | 1 |
| Belitsky, G; Budunova, I; Gordon, LI; Kirsanov, K; Lesovaya, E; Popa, A; Rosen, ST; Yakubovskaya, M; Yemelyanov, A | 1 |
| Cheson, BD | 1 |
| Anderson, KC; Chauhan, D; Hideshima, T; Li, G; Ohtake, Y; Podar, K; Shringarpure, R | 1 |
| An, J; Fisher, M; Rettig, MB; Sun, Y | 1 |
| Anderson, KC; Burger, R; Catley, L; Chauhan, D; Denis, L; Hideshima, T; Munshi, NC; Podar, K; Richardson, P; Shringarpure, R; Son, MT; Tai, YT; Tassone, P | 1 |
| Heinrich, B | 1 |
| Albert, V; Andreeff, M; Carbone, A; Georgakis, GV; Humphreys, R; Li, Y; O'Brien, S; Younes, A; Younes, M | 1 |
| Adams, J; Boyden, J; Chachoua, A; Clark, JW; Eder, JP; Elliott, P; Farrell, K; Garcia-Carbonero, R; Hamilton, AL; Kinchla, N; Liebes, L; Muggia, FM; Pavlick, AC; Ryan, DP; Soma, V; Wright, J; Yee, H; Zeleniuch-Jacquotte, A | 1 |
| Balkwill, F; Boral, A; Hoare, S; Joel, SP; Johnson, PW; Lister, TA; Maharaj, L; Millard, L; Radford, JA; Rohatiner, A; Schenkein, D; Strauss, SJ; Trehu, E; Vinnecombe, S | 1 |
| Amadori, S; Boccadoro, M; Caravita, T; de Fabritiis, P; Palumbo, A | 1 |
| Angitapalli, R; Dhodapkar, MV; Hutchinson, A; Jagannath, S; Kukreja, A; Mazumder, A; O'connor, OA; Vesole, D | 1 |
| Abou-Merhi, R; Arnoult, D; Bazarbachi, A; Dbouk, H; de Thé, H; El Hajj, H; El-Sabban, ME; Gessain, A; Hermine, O; Khoriaty, R; Mahieux, R; Munier, S | 1 |
| Tobinai, K | 2 |
| Abayomi, EA; Jacobs, P; Sissolak, G | 1 |
| Barr, P; Fisher, R; Friedberg, J | 1 |
| Blau, IW; Busse, A; Driessen, C; Keilholz, U; Kraus, M; Na, IK; Rietz, A; Scheibenbogen, C; Thiel, E | 1 |
| Godal, T; Heikkilä, R; Iversen, JG | 1 |
| Kelloff, G; Rao, CV; Reddy, BS; Rivenson, A; Steele, V; Zang, E | 1 |
| Kensler, TW; Roebuck, BD; Rogers, AE | 1 |
12 review(s) available for pyrazines and Lymphoma
| Article | Year |
|---|---|
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
The future of small molecule inhibitors in lymphoma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Discovery; Forecasting; Histone Deacetylases; Humans; Lymphoma; Oligopeptides; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2009 |
Targeted therapy in lymphoma.
Topics: Boronic Acids; Bortezomib; Everolimus; Humans; Lymphoma; Molecular Targeted Therapy; Pyrazines; Signal Transduction; Sirolimus; Survival Analysis | 2010 |
[Malignant lymphoma: individualized treatment according to biological and clinical risk factors].
Topics: Age Factors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Ki-1 Antigen; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Precision Medicine; Prognosis; Pyrazines; Risk Factors; Rituximab; Survival Rate; Waldenstrom Macroglobulinemia | 2011 |
Bortezomib-induced Epstein-Barr virus and Kaposi sarcoma herpesvirus lytic gene expression: oncolytic strategies.
Topics: Boronic Acids; Bortezomib; Carcinoma; Epstein-Barr Virus Infections; Gene Expression Regulation, Viral; Herpesvirus 4, Human; Herpesvirus 8, Human; Humans; Incidence; Lymphoma; Proteasome Inhibitors; Pyrazines; Sarcoma, Kaposi; Virus Latency; Virus Physiological Phenomena | 2011 |
[Development and clinical application of novel proteasome inhibitors].
Topics: Boronic Acids; Bortezomib; Drug Design; Drug Therapy, Combination; Drug Tolerance; Lymphoma; Molecular Targeted Therapy; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Randomized Controlled Trials as Topic | 2012 |
Hematologic malignancies: new developments and future treatments.
Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides | 2002 |
Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dose-Response Relationship, Drug; Hematologic Neoplasms; Humans; Lymphoma; Multiple Myeloma; Neoplasms; Protease Inhibitors; Pyrazines; Treatment Outcome | 2006 |
[Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Design; Humans; Lymphoma; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2007 |
Use of novel proteosome inhibitors as a therapeutic strategy in lymphomas current experience and emerging concepts.
Topics: Active Transport, Cell Nucleus; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Cell Cycle; Cell Differentiation; Clinical Trials, Phase II as Topic; Endoplasmic Reticulum; Humans; Lymphoma; Neoplasm Proteins; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2007 |
Proteasome inhibitor, bortezomib, for myeloma and lymphoma.
Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2007 |
The role of bortezomib in the treatment of lymphoma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Mantle-Cell; Protease Inhibitors; Pyrazines | 2007 |
3 trial(s) available for pyrazines and Lymphoma
| Article | Year |
|---|---|
[Current development of new drugs in malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat | 2012 |
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lymphoma; Male; Middle Aged; Neoplasms; Peripheral Nervous System; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2005 |
Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Cytokines; Doxorubicin; Female; Humans; Lymphoma; Male; Middle Aged; Pyrazines; Recurrence; Tumor Necrosis Factor-alpha | 2006 |
28 other study(ies) available for pyrazines and Lymphoma
| Article | Year |
|---|---|
WNT974 Inhibits Proliferation, Induces Apoptosis, and Enhances Chemosensitivity to Doxorubicin in Lymphoma Cells by Inhibiting Wnt/β-Catenin Signaling.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Lymphoma; Pyrazines; Pyridines; Wnt Signaling Pathway | 2020 |
Simple benchmark for complex dose finding studies.
Topics: Algorithms; Antineoplastic Agents; Bayes Theorem; Benchmarking; Biometry; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Computer Simulation; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Lymphoma; Models, Statistical; Pyrazines; Stroke; Urinary Bladder Neoplasms | 2014 |
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Health; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Membrane Potential, Mitochondrial; Mice; Microscopy, Confocal; Molecular Mimicry; Nitrophenols; Piperazines; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; Tissue Donors; Xenograft Model Antitumor Assays | 2008 |
Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cellular Senescence; DNA Fragmentation; Flow Cytometry; Humans; Inhibitory Concentration 50; Killer Cells, Natural; Lymphoma; Mitosis; Models, Biological; Multiple Myeloma; Pyrazines | 2008 |
PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
Topics: Aged; Antineoplastic Agents; Apoptosis; Benzofurans; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Female; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma; Lymphoma, Non-Hodgkin; Male; Membrane Potential, Mitochondrial; Middle Aged; NF-kappa B; Pyrazines; Reactive Oxygen Species; Tumor Cells, Cultured | 2009 |
Cytotoxic effects of celecoxib on Raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2.
Topics: Boronic Acids; Bortezomib; Celecoxib; Cell Death; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; Endoplasmic Reticulum; Humans; Lymphoma; Pyrazines; Pyrazoles; Stress, Physiological; Sulfonamides | 2010 |
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
Topics: Animals; Boron Compounds; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Drug Screening Assays, Antitumor; Female; Glycine; HCT116 Cells; HT29 Cells; Humans; Lymphoma; Mice; Mice, SCID; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays | 2010 |
Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Lymphoma; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptor, Fibroblast Growth Factor, Type 3; STAT1 Transcription Factor; STAT3 Transcription Factor; U937 Cells | 2010 |
[Effect of bortezomib on lymphoma cell line CA46 and its relative mechanisms].
Topics: Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Lymphoma; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2010 |
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; HL-60 Cells; Humans; Immunohistochemistry; Inhibitory Concentration 50; K562 Cells; Ki-67 Antigen; Lenalidomide; Leukemia, Myeloid; Lymphoma; Multiple Myeloma; Phosphorylcholine; Pyrazines; Thalidomide; Time Factors | 2012 |
Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Child; Enzyme Activation; Epstein-Barr Virus Infections; Female; Humans; Killer Cells, Natural; Lymphoma; Lymphoma, T-Cell; Male; NF-kappa B; Proteasome Inhibitors; Pyrazines; T-Lymphocytes | 2011 |
Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Caspases; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Chemokine CXCL12; Chymotrypsin; Coculture Techniques; DNA Fragmentation; Drug Synergism; Enzyme Activation; Female; Humans; JNK Mitogen-Activated Protein Kinases; Lymphoma; Mice; Mice, SCID; Oligopeptides; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteasome Inhibitors; Pyrazines; Serine Proteinase Inhibitors; Unfolded Protein Response; Waldenstrom Macroglobulinemia | 2011 |
A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy.
Topics: Animals; Boronic Acids; Bortezomib; Iodine Radioisotopes; Lymphoma; Mice; Models, Biological; Monte Carlo Method; Pyrazines; Radiometry; Radiopharmaceuticals | 2011 |
Acquired STAT4 deficiency as a consequence of cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Carmustine; Cells, Cultured; Drug Interactions; Etoposide; Flow Cytometry; Gene Expression; Humans; Interleukin-12; Interleukin-2; Leukocytes, Mononuclear; Lymphoma; Melanoma; Mice; Mice, Inbred C57BL; Protein Biosynthesis; Pyrazines; RNA Stability; Skin Neoplasms; STAT4 Transcription Factor; Ubiquitin | 2011 |
Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Flow Cytometry; Gene Expression; Humans; I-kappa B Proteins; Lymphoma; Mitochondria; NF-kappa B; NF-KappaB Inhibitor alpha; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin | 2012 |
Rad knockdown induces mitochondrial apoptosis in bortezomib resistant leukemia and lymphoma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Jurkat Cells; K562 Cells; Leukemia; Lymphoma; Mitochondria; Pyrazines; ras Proteins; RNA, Small Interfering; Up-Regulation | 2012 |
Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; Dimerization; Drug Synergism; Hematologic Neoplasms; Humans; K562 Cells; Lymphoma; NF-kappa B; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Receptors, Glucocorticoid; RNA Interference; RNA, Small Interfering; Transcription Factor AP-1; Transcriptional Activation; Triazoles; Tumor Cells, Cultured | 2013 |
Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Leupeptins; Lymphoma; Molecular Chaperones; Multienzyme Complexes; Neoplasm Proteins; Proteasome Endopeptidase Complex; Pyrazines; RNA, Messenger; Transfection | 2003 |
Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Division; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Drug Synergism; Humans; Lymphoma; Membrane Glycoproteins; NF-kappa B; Paclitaxel; Pleural Effusion, Malignant; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2004 |
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Camptothecin; Cell Communication; Cell Line, Tumor; DNA Topoisomerases, Type I; DNA, Neoplasm; Doxorubicin; Drug Synergism; Enzyme Activation; fas Receptor; Humans; Irinotecan; JNK Mitogen-Activated Protein Kinases; Lymphoma; Multiple Myeloma; Poly(ADP-ribose) Polymerases; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Stromal Cells; Up-Regulation | 2004 |
[Therapeutic outcomes in systemic lymphatic diseases and plasmacytoma. New hope for palliative patients].
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lymphoma; Multiple Myeloma; Prognosis; Pyrazines; Radioimmunotherapy; Thalidomide | 2005 |
Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
Topics: Analysis of Variance; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; Fluorescent Antibody Technique; Humans; Lymphoma; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Statistics, Nonparametric; Tumor Cells, Cultured | 2005 |
Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Communication; Cell Line, Tumor; Colony-Forming Units Assay; Dendritic Cells; Flow Cytometry; Humans; Lymphoma; Multiple Myeloma; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2007 |
PS-341 or a combination of arsenic trioxide and interferon-alpha inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV-8-infected primary effusion lymphoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Herpesvirus 8, Human; Humans; Interferon-alpha; Lymphoma; Membrane Potential, Mitochondrial; NF-kappa B; Oxides; Protease Inhibitors; Pyrazines | 2007 |
Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits.
Topics: Acetylcysteine; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Line, Tumor; Cysteine Endopeptidases; Drug Screening Assays, Antitumor; Humans; Interferon-gamma; Lymphoma; Multienzyme Complexes; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein Subunits; Pyrazines | 2008 |
Amiloride inhibits anti-Ig induction of proliferation in a human B-lymphoma cell population.
Topics: Amiloride; Antibodies, Anti-Idiotypic; B-Lymphocytes; Biological Transport; DNA; Humans; Lymphocyte Activation; Lymphoma; Pyrazines; Rubidium; Tetradecanoylphorbol Acetate; Thymidine | 1983 |
Inhibition of 2-Amino-1-methyl-6-phenylimidazo[4,5]pyridine-induced lymphoma formation by oltipraz.
Topics: Animals; Anticarcinogenic Agents; Body Weight; Carcinogens; Imidazoles; Intestinal Neoplasms; Lymphoma; Male; Pyrazines; Rats; Rats, Inbred F344; Thiones; Thiophenes | 1996 |
Correspondence re: C.V. Rao, et al., Inhibition of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced lymphoma formation by oltipraz. Cancer Res., 56: 3395-3398, 1996.
Topics: Aflatoxin B1; Animals; Anticarcinogenic Agents; Hematologic Neoplasms; Imidazoles; Lymphoma; Male; Pyrazines; Rats; Rats, Inbred F344; Thiones; Thiophenes | 1997 |